# **SESSION LECTURE**

No.36

Pharmacology of Natural Products and Traditional Medicines Room: Dong Yu Grand Ballroom 1

Co-Chairs: Wenxia Zhou



Valérie B. Schini-Kerth



Day 3 October 21st (Monday) 09:00 – 12:40		
Time	Speaker	Title
09:00-09:30	Baofeng Yang Harbin Medical University, China	Research and inspiration on healthy ageing
09:30-10:00	Valérie B. Schini-Kerth University of Strasbourg, France	Potential of natural products to improveaging-related impairment of the vascularand cardiac function
10:00-10:30	Junhua Zhang Tianjin University of Traditional Chinese Medicine, China	Study on the Mechanism of Xuanfei Baidu Granule in Treating COVID-19
10:30-10:50	Tea Break	
10:50-11:10	Cherry Wainwright Robert Gordon University, UK	Modern approaches to Natural Product Drug Discovery - Learning Lessons from Small Molecule Discovery programmes
11:10-11:40	Zhiyong Xiao Beijing Institute of Pharmacology and Toxicology, China	Advancements in Pharmacological Research on Traditional Chinese Medicine Polysaccharides for Combatting COVID-19
11:40-12:10	<b>David Adelson</b> University of Adelaide, Australia	Systems and computational biology approaches to understanding the molecular mode of action of Yanshu (Compound Kushen) Injection
12:10-12:25	Yuka Harata-Lee University of Adelaide, Australia	Therapeutic effect of Yanshu Injection and Yanshu Powder on radiation induced Gastrointestinal mucositis
12:25-12:40	Hanyuan Shen University of Adelaide, Australia	Using CRISPR-Cas to validate candidatemolecurlar pathways affected by Yanshu Injection



Wenxia Zhou

zhouwx727@163.com

Wenxia Zhou is a professor of Department of Neuroimmunopharmacology and traditionalChinese medicine, Beijing Institute of Pharmacology and Toxicology. Her research interests include the study of function ofneuroendocrine immunododulation (NIM) network and the pharmacological studies of immunomodulators, endocrinomoduators, anti-ageing (especially anti-Alzheimer's disease)and cognitionenhancing drugs. Dr. Zhou has published over 180 peer-reviewed publications. She is also Secretary-General of Natural Products Section of the International Union of Basic and Clinical Pharmacology (IUPHAR).



#### Valérie Schini-Kerth

valerie.schini-kerth@unistra.fr

Prof. Schini-Kerth is a Professor of Pharmacologyat the Faculty of Pharmacy of Strasbourg University. She is a member of the INSERM Regenerative Nanomedicine research unit (UMR 1260). Her major research interest is focusing on the pivotal role of the endothelium in the control of vascular homeostasisin health and disease. Her recent interest is focusing on the role of premature endothelial senescence in the initiation of endothelial dysfunction and its pharmacological inhibition by drugs and natural products including berry-derived products. She is currently the Chair of the Natural Products Section of IUPHAR.



**Baofeng Yang** 

yangbf@ems.hrbmu.edu.cn

Prof. Baofeng Yang, Academician of Chinese Academy of Engineering, Honorary Professor of famous universities in the USA, Russia, Australia and Japan. Professor Yang is Director of State Key Laboratory of Frigid Zone Cardiovascular Diseases, Chief scientist of "973" program project. Prof. Yang evaluated the effects of over 50 drugs on the cardiovascular system and proposed the theory "Best Target of Antiarrhythmic Drug Action"; Prof. Yang developed a few drugs such as Daming capsule, Kangxin capsule and Nianlianping; Prof. Yang has published over 500 papers in Nature Medicine, Circulation, JACC, et al. Prof. Yang was the editor-in-chief of the medical textbook—Pharmacology (Sixth, Seventh, Eighth, Ninth, and Tenth Edition).



Junhua Zhang

zjhtcm@foxmail.com

Junhua Zhang, Vice-president of Tianjin University of traditional Chinese medicine; Executive director of State Key Laboratory of Chinese Medicine Modernization; Director of the Evidence-based evaluation of TCM Key Laboratory of National Medical Products Administration. Dr. Zhang has engaged in the field of Evidence-based Chinese Medicine and participated in more than 10 multicenter clinical trials. He has won 5 national and provincial science and technology awards, published 3 books as chief editor and more than 200 papers. He has been awarded several honorary titles, such as National Distinguished Professor and Tianjin Outstanding Talent.



Cherry Wainwright

c.wainwright@rgu.ac.uk

Professor Cherry Wainwright has a BSc (Hons) in Pharmacology and a PhD in Cardiovascular Pharmacology. Her research career spans more than 42 years, conducting research on the identification of novel therapeutic targets of cardiovascular diseases, including myocardial ischaemia/reperfusion, cardiac fibrosis, vascular injury and cardiac energy regulation, and the search for novel agents from natural sources had played a significant part throughout her research. She has published around 100 full original articles and invited reviews and has 3 patents. She is a Fellow of the British Pharmacological Society, for which is currently President Elect.



Zhiyong Xiao

zy-xiao@163.com

Xiao Zhiyong, an Associate Researcher, Master's Supervisor, and Laboratory Director with a PhD. She spent March 2017 to March 2018 as a Visiting Scholar at the New Jersey Cancer Institute focusing on tumor molecular biology. Her research primarily explores polysaccharide recognition patterns and immune regulatory mechanisms in response to viral infections. Over the past five years, she has participated in four significant national research projects and played a crucial role in developing LW-AFC, China's first traditional medicine derived from classical prescriptions, which received two clinical trial approvals. She has authored over 40 research papers, filed for 10 software copyrights, and obtained three national invention patents.



### David Adelson

### david.adelson@adelaide.edu.au

David Adelson is Professor and Chair of Bioinformatics and Computational Genetics and Zhendong Chair of Molecular Traditional Chinese Medicine in the School of Biological Sciences at the University of Adelaide and previously was a Xinglin Scholar Professor at Guangzhou University of TCM. Prof. Adelson's current research has two foci: transposable elements' impact on large scale evolutionary/structural changes in animal genomes, and systems biology of Traditional Chinese Medicine. As Director of the Zhendong Centre of Molecular Traditional Chinese Medicine, Prof Adelson's laboratory has pioneered our understanding of the molecular mode of action of Yanshu (Compound Kushen) Injection, an important TCM drug.



## Yuka Harata-Lee

## yuka.harata-lee@adelaide.edu.au

Dr. Yuka Harata-Lee is currently a post-doctoral research fellow in the Department of Molecular and Biomedical Sciences in The University of Adelaide. She is also the lab manager of Zhendong Australia-China Molecular Traditional Chinese medicine Research center. Dr Harate-Lee has authored or co-authored 19 publications in influential international journals including but not limited to Journal of Experimental Medicine, Blood, Oncogene covering various research areas of cancer biology. Dr Harate-Lee is also holding a patent for developing novel methods and products for preventing and/or treating metastatic cancer (Patent number: 9718887). In 2014, Dr Harate-Lee was awarded the Chris and Bhama Parish ICB publication of the Year Award.



## Hanyuan Shen

## hanyuan.shen@adelaide.edu.au

Dr. Hanyuan Shen has been a post-doctoral research fellow in the Department of Molecular and Biomedical Sciences at The University of Adelaide since 2020. He is working in the Zhendong Australia-China Molecular Traditional Chinese Medicine Research Center, where his primary research focus is on employing omics methods to uncover the mechanisms of Chinese medicine and natural products. Dr. Hanyuan Shen has authored or co-authored nine publications in peer-reviewed journals.